{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:28:59Z","timestamp":1790803739372,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Elexacaftor (ELX)\/tezacaftor (TEZ)\/ivacaftor (IVA) was shown to be safe and efficacious in children 6 through 11 years of age with cystic fibrosis (CF) and at least one F508del allele in a 24-week phase 3 study. Children completing this study could enroll into a 192-week extension study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the long-term safety and efficacy of ELX\/TEZ\/IVA in children \u22656 years of age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this two-part (part A [96 wk] and part B [96 wk]) phase 3 extension study, children &amp;lt;12 years of age weighing &amp;lt;30 kg received ELX 100 mg once daily\/TEZ 50 mg once daily\/IVA 75 mg every 12 hours, and children weighing \u226530 kg or aged \u226512 years received ELX 200 mg once daily\/TEZ 100 mg once daily\/IVA 150 mg every 12 hours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Sixty-four children (F508del\/minimal function [n\u2009=\u200936] and F508del\/F508del [n\u2009=\u200928]) received at least one dose of ELX\/TEZ\/IVA. Mean exposure was 156.2 weeks, and 60.9% of children (n\u2009=\u200939) completed treatment in both parts of this 192-week study. The primary endpoint was safety. All children had adverse events, which for most were mild (31.3%) or moderate (64.1%) and generally consistent with common manifestations of CF. Two children (3.1%) had nonserious adverse events that led to treatment discontinuation (increased alanine aminotransferase [n\u2009=\u20091] and aggression [n\u2009=\u20091]). Secondary endpoints focused on efficacy. From parent study baseline, improvements were seen in percentage predicted FEV1 (9.6 percentage points [95% confidence interval (CI), 5.4 to 13.7 percentage points]), sweat chloride concentration (\u221257.9 mmol\/L [95% CI, \u221263.3 to \u221252.5 mmol\/L]), Cystic Fibrosis Questionnaire\u2013Revised respiratory domain score (10.0 points [95% CI, 6.9 to 13.0 points]), lung clearance index at a 2.5% stopping point (\u22122.33 [95% CI, \u22122.87 to \u22121.79]), and body mass index z-score (0.39 [95% CI, 0.19 to 0.59]) at Week 192. The rate of pulmonary exacerbations per year was 0.05. The annualized rates of change in percentage predicted FEV1 and lung clearance index at a 2.5% stopping point were \u22120.09 percentage points (95% CI, \u22121.01 to 0.84 percentage points) and \u22120.07 units (95% CI, \u22120.12 to \u22120.01 units), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this 4-year extension study in children \u22656 years of age, the longest clinical trial experience with a CFTR (cystic fibrosis transmembrane conductance regulator) modulator in this pediatric population, ELX\/TEZ\/IVA remained generally safe and well tolerated, with no new safety findings. Clinically meaningful improvements in lung function, CFTR function, and nutritional status reported in the parent study were maintained. These results confirm the long-term safety and efficacy of ELX\/TEZ\/IVA in children \u22656 years of age.Clinical trial registered with www.clinicaltrials.gov (NCT 04183790).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202502-0512oc","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T16:48:25Z","timestamp":1749833305000},"page":"1915-1925","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":13,"title":["Long-Term Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in Children \u22656 Years with Cystic Fibrosis and at Least One\n                    <i>F508del<\/i>\n                    Allele: A 192-Week, Phase 3, Open-Label Extension Study"],"prefix":"10.1093","volume":"211","author":[{"given":"Claire","family":"Wainwright","sequence":"first","affiliation":[{"name":"Queensland Children\u2019s Hospital, South Brisbane, Queensland, Australia"},{"name":"University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna A.","family":"McColley","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, Illinois"},{"name":"Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7102-1712","authenticated-orcid":false,"given":"Paul","family":"McNally","sequence":"additional","affiliation":[{"name":"RSCI University of Medicine and Health Sciences, Dublin, Ireland"},{"name":"Children\u2019s Health Ireland, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Powers","sequence":"additional","affiliation":[{"name":"Oregon Health & Sciences University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Ratjen","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Rayment","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Retsch-Bogart","sequence":"additional","affiliation":[{"name":"University of North Carolina, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Roesch","sequence":"additional","affiliation":[{"name":"University Hospitals Cleveland Medical Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Hospital, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5455-8208","authenticated-orcid":false,"given":"Edward F.","family":"McKone","sequence":"additional","affiliation":[{"name":"St. Vincent\u2019s University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Tullis","sequence":"additional","affiliation":[{"name":"St. Michael\u2019s Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-2199","authenticated-orcid":false,"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[{"name":"Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"German Center for Child and Adolescent Health, Partner Site, Berlin, Germany"},{"name":"German Center for Lung Research, Associated Partner Site Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5436-9722","authenticated-orcid":false,"given":"Jennifer L.","family":"Taylor-Cousar","sequence":"additional","affiliation":[{"name":"National Jewish Health, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Waltz","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals, Inc., Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Ahluwalia","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals, Inc., Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghao","family":"Chu","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals, Inc., Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina V.","family":"Scirica","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals, Inc., Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane C.","family":"Davies","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London and Royal Brompton Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"2026013020465512000_bib1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2021.23280","article-title":"What is cystic fibrosis?","volume":"327","author":"Endres","year":"2022","journal-title":"JAMA"},{"key":"2026013020465512000_bib2","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1152\/ajpcell.00417.2002","article-title":"Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease","volume":"284","author":"Verkman","year":"2003","journal-title":"Am J Physiol Cell Physiol"},{"key":"2026013020465512000_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1542\/pir.2019-0212","article-title":"Cystic fibrosis","volume":"42","author":"Dickinson","year":"2021","journal-title":"Pediatr Rev"},{"key":"2026013020465512000_bib4","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026013020465512000_bib5","article-title":"About cystic fibrosis","author":"Cystic Fibrosis Foundation","year":"2024"},{"key":"2026013020465512000_bib6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/ijns6010018","article-title":"Newborn screening for CF across the globe\u2014where is it worthwhile?","volume":"6","author":"Scotet","year":"2020","journal-title":"Int J Neonatal Screen"},{"key":"2026013020465512000_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1891\/NN-2022-0007","article-title":"Cystic fibrosis: back to the basics","volume":"42","author":"Myer","year":"2023","journal-title":"Neonatal Netw"},{"key":"2026013020465512000_bib8","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2026013020465512000_bib9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in children aged \u22656 years with cystic fibrosis and at least one F508del allele: a phase 3, open-label clinical trial","volume":"208","author":"Wainwright","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020465512000_bib10","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"2026013020465512000_bib11","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"2026013020465512000_bib12","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020465512000_bib13","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020465512000_bib14","doi-asserted-by":"crossref","first-page":"2202029","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur Respir J"},{"key":"2026013020465512000_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2 through 5 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020465512000_bib16","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1152\/japplphysiol.00338.2021","article-title":"Correction of sensor crosstalk error in Exhalyzer D multiple-breath washout device significantly impacts outcomes in children with cystic fibrosis","volume":"131","author":"Wyler","year":"2021","journal-title":"J Appl Physiol (1985)"},{"key":"2026013020465512000_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1152\/japplphysiol.00129.2021","article-title":"Improved agreement between N2 and SF6 multiple-breath washout in healthy infants and toddlers with improved Exhalyzer D sensor performance","volume":"131","author":"Sandvik","year":"2021","journal-title":"J Appl Physiol (1985)"},{"key":"2026013020465512000_bib18","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/j.jcf.2021.08.033","article-title":"Impact of cross-sensitivity error correction on representative nitrogen-based multiple breath washout data from clinical trials","volume":"21","author":"Robinson","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026013020465512000_bib19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1542\/pir.32.8.325","article-title":"Aggressive behavior in children and adolescents","volume":"32","author":"Zahrt","year":"2011","journal-title":"Pediatr Rev"},{"key":"2026013020465512000_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1164\/rccm.202308-1525OC","article-title":"Elexacaftor\/tezacaftor\/ivacaftor treatment and depression-related events","volume":"209","author":"Ramsey","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020465512000_bib21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00127-022-02307-w","article-title":"Depression and anxiety prevalence in people with cystic fibrosis and their caregivers: a systematic review and meta-analysis","volume":"58","author":"Lord","year":"2023","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"2026013020465512000_bib22","doi-asserted-by":"crossref","first-page":"e213917","DOI":"10.1001\/jamanetworkopen.2021.3917","article-title":"Trends in blood pressure and hypertension among US children and adolescents, 1999\u20132018","volume":"4","author":"Hardy","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026013020465512000_bib23","doi-asserted-by":"crossref","first-page":"e20171904","DOI":"10.1542\/peds.2017-1904","article-title":"Clinical practice guideline for screening and management of high blood pressure in children and adolescents","volume":"140","author":"Flynn","year":"2017","journal-title":"Pediatrics"},{"key":"2026013020465512000_bib24","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/13816810.2017.1301964","article-title":"Diagnosed cataracts in patients with cystic fibrosis in a United States administrative database","volume":"38","author":"Everage","year":"2017","journal-title":"Ophthalmic Genet"},{"key":"2026013020465512000_bib25","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/S1569-1993(15)30373-8","article-title":"Prevalence of cataracts in a population of cystic fibrosis patients homozygous for the F508del mutation","volume":"14","author":"Seliger","year":"2015","journal-title":"J Cyst Fibros"},{"key":"2026013020465512000_bib26","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1164\/rccm.201606-1107CI","article-title":"Early lung disease in infants and preschool children with cystic fibrosis: what have we learned and what should we do about it?","volume":"195","author":"Ranganathan","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020465512000_bib27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13052-019-0647-5","article-title":"Lung clearance index in subjects with cystic fibrosis in Italy","volume":"45","author":"Lombardi","year":"2019","journal-title":"Ital J Pediatr"},{"key":"2026013020465512000_bib28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1164\/rccm.200407-948OC","article-title":"Ventilation inhomogeneities in relation to standard lung function in patients with cystic fibrosis","volume":"171","author":"Kraemer","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020465512000_bib29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1164\/rccm.201604-0893OC","article-title":"Comparison of lung clearance index and magnetic resonance imaging for assessment of lung disease in children with cystic fibrosis","volume":"195","author":"Stahl","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020465512000_bib30","doi-asserted-by":"crossref","first-page":"2002686","DOI":"10.1183\/13993003.02686-2020","article-title":"Longitudinal course of clinical lung clearance index in children with cystic fibrosis","volume":"58","author":"Frauchiger","year":"2021","journal-title":"Eur Respir J"},{"key":"2026013020465512000_bib31","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"2026013020465512000_bib32","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation","volume":"181S","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"key":"2026013020465512000_bib33","first-page":"503","article-title":"Association of growth and nutritional parameters with pulmonary function in cystic fibrosis: a literature review","volume":"34","author":"Mauch","year":"2016","journal-title":"Rev Paul Pediatr"},{"key":"2026013020465512000_bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13052-021-00970-4","article-title":"COVID-19 lockdown beneficial effects on lung function in a cohort of cystic fibrosis patients","volume":"47","author":"Servidio","year":"2021","journal-title":"Ital J Pediatr"},{"key":"2026013020465512000_bib35","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.3390\/ijms21165882","article-title":"From ivacaftor to triple combination: a systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis","volume":"21","author":"Gramegna","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026013020465512000_bib36","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2026013020465512000_bib37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cpcardiol.2018.11.002","article-title":"Increasing diversity in clinical trials: overcoming critical barriers","volume":"44","author":"Clark","year":"2019","journal-title":"Curr Probl Cardiol"},{"key":"2026013020465512000_bib38","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1017\/cts.2022.510","article-title":"Barriers to and solutions for representative inclusion across the lifespan and in life course research: the need for structural competency highlighted by the COVID-19 pandemic","volume":"7","author":"LeCroy","year":"2023","journal-title":"J Clin Transl Sci"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/10\/1915\/66621229\/ajrccm_211_10_1915.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/10\/1915\/66621229\/ajrccm_211_10_1915.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T01:47:10Z","timestamp":1769824030000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/211\/10\/1915\/8444177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,1]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202502-0512oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"2025-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}